Palmar Psoriasis After COVID-19 Vaccine – Case Report
- A recently documented case highlights a potential, though rare, adverse event following mRNA COVID-19 vaccination: the new onset of palmar psoriasis.
- In February 2024, a 54-year-old man developed palmar psoriasis approximately two weeks after receiving his first dose of an mRNA COVID-19 vaccine. He had no prior personal or...
- Dermatological examination confirmed the diagnosis of palmar psoriasis.
Rare Skin Reaction: Palmar Psoriasis Linked to mRNA COVID-19 Vaccine
Table of Contents
Published August 23, 2025
Understanding the Connection
A recently documented case highlights a potential, though rare, adverse event following mRNA COVID-19 vaccination: the new onset of palmar psoriasis. Palmar psoriasis is a form of psoriasis that specifically affects the palms of the hands, causing raised, scaly patches that can be painful and debilitating. While psoriasis has numerous known triggers, this case suggests a possible temporal link to vaccination.
The Case Study
In February 2024, a 54-year-old man developed palmar psoriasis approximately two weeks after receiving his first dose of an mRNA COVID-19 vaccine. He had no prior personal or family history of psoriasis, nor any known risk factors for the condition. The patient’s symptoms included well-defined, erythematous plaques with silvery scales on both palms.
Dermatological examination confirmed the diagnosis of palmar psoriasis. The patient was treated with topical corticosteroids, resulting in significant enhancement of his symptoms. Importantly,the case report emphasizes that while the onset occured after vaccination,it doesn’t definitively prove a causal relationship.
What Does This mean?
This case report doesn’t indicate a widespread issue, but it does raise awareness of a potential, albeit uncommon, adverse reaction. The authors note that the temporal association warrants further investigation to determine if there is a genuine link between mRNA vaccines and the development of palmar psoriasis in susceptible individuals. It’s crucial to remember that the benefits of COVID-19 vaccination continue to outweigh the risks for the vast majority of people.
Healthcare professionals shoudl be aware of this potential presentation and consider it in the differential diagnosis of patients presenting with new-onset palmar psoriasis following mRNA vaccination. Reporting any suspected adverse events to the appropriate authorities, such as the Vaccine Adverse Event Reporting System (VAERS), is essential for ongoing safety monitoring.
Psoriasis and the Immune System
Psoriasis is an autoimmune disease characterized by accelerated skin cell growth. It’s understood that the immune system plays a central role in its development. mRNA vaccines work by stimulating an immune response to a specific viral protein, which could theoretically trigger or exacerbate autoimmune conditions in individuals with a predisposition. however, this remains a complex area of research.
Staying Informed
This case serves as a reminder of the importance of continued vigilance in monitoring vaccine safety. Individuals experiencing new or unusual symptoms after vaccination should consult with their healthcare provider for proper evaluation and management. Further research is needed to fully understand the potential relationship between mRNA COVID-19 vaccines and the development of palmar psoriasis.
